123 related articles for article (PubMed ID: 38485575)
1. Re: Assessment of PD-L1, TROP2, and NECTIN-4 Expression in Penile Squamous Cell Carcinoma.
Linxweiler J; Klümper N; Mink J; Eckstein M; Junker K
Eur Urol; 2024 Jun; 85(6):586-587. PubMed ID: 38485575
[No Abstract] [Full Text] [Related]
2. Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma.
Tekin B; Cheville JC; Herrera Hernandez L; Negron V; Smith CY; Jenkins SM; Dasari S; Enninga EAL; Norgan AP; Menon S; Cubilla AL; Whaley RD; Jimenez RE; Thompson RH; Leibovich BC; Karnes RJ; Boorjian SA; Pagliaro LC; Erickson LA; Guo R; Gupta S
Hum Pathol; 2023 Dec; 142():42-50. PubMed ID: 37977513
[TBL] [Abstract][Full Text] [Related]
3. Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.
Bahlinger V; Branz A; Strissel PL; Strick R; Lange F; Geppert CI; Klümper N; Hölzel M; Wach S; Taubert H; Sikic D; Wullich B; Angeloni M; Ferrazzi F; Diehl L; Kovalenko M; Elboudwarej E; Jürgensmeier JM; Hartmann A; Eckstein M
Histopathology; 2024 Apr; 84(5):863-876. PubMed ID: 38196202
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 Expression in Men with Penile Cancer and its Association with Clinical Outcomes.
Davidsson S; Carlsson J; Giunchi F; Harlow A; Kirrander P; Rider J; Fiorentino M; Andrén O
Eur Urol Oncol; 2019 Mar; 2(2):214-221. PubMed ID: 31017099
[TBL] [Abstract][Full Text] [Related]
5. Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches.
Udager AM; Liu TY; Skala SL; Magers MJ; McDaniel AS; Spratt DE; Feng FY; Siddiqui J; Cao X; Fields KL; Morgan TM; Palapattu GS; Weizer AZ; Chinnaiyan AM; Alva A; Montgomery JS; Tomlins SA; Jiang H; Mehra R
Ann Oncol; 2016 Sep; 27(9):1706-12. PubMed ID: 27217541
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 and p16 Expression in Penile Squamous Cell Carcinoma From an Endemic Region.
De Bacco MW; Carvalhal GF; MacGregor B; Marçal JMB; Wagner MB; Sonpavde GP; Fay AP
Clin Genitourin Cancer; 2020 Jun; 18(3):e254-e259. PubMed ID: 32139302
[TBL] [Abstract][Full Text] [Related]
7. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.
Cocks M; Taheri D; Ball MW; Bezerra SM; Del Carmen Rodriguez M; Ricardo BFP; Bivalacqua TJ; Sharma RB; Meeker A; Chaux A; Burnett AL; Netto GJ
Hum Pathol; 2017 Jan; 59():55-61. PubMed ID: 27663086
[TBL] [Abstract][Full Text] [Related]
8. The peri- and intratumoral immune cell infiltrate and PD-L1 status in invasive squamous cell carcinomas of the penis.
Müller T; Demes M; Lehn A; Köllermann J; Vallo S; Wild PJ; Winkelmann R
Clin Transl Oncol; 2022 Feb; 24(2):331-341. PubMed ID: 34449004
[TBL] [Abstract][Full Text] [Related]
9. Loss of Trop2 promotes carcinogenesis and features of epithelial to mesenchymal transition in squamous cell carcinoma.
Wang J; Zhang K; Grabowska D; Li A; Dong Y; Day R; Humphrey P; Lewis J; Kladney RD; Arbeit JM; Weber JD; Chung CH; Michel LS
Mol Cancer Res; 2011 Dec; 9(12):1686-95. PubMed ID: 21970857
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of programmed cell death ligand 1 expression in a contemporary cohort of penile squamous cell carcinoma and its correlation with clinicopathologic and survival parameters: A study of 134 patients.
Lobo A; Mishra SK; Jha S; Tiwari A; Kapoor R; Sharma S; Kaushal S; Kiranmai NS; Das MR; Peddinti KP; Sharma SK; Bhardwaj N; Arora S; Jain D; Jain E; Munjal G; Shinde S; Malik V; Singh H; Varshney J; Pradhan D; Dixit M; Pattnaik N; Sharma AK; Barapatre YR; Pradhan M; Satapathy K; Rath D; Jaiswal S; Das S; Khadenga C; Routa S; Baisakh MR; Tiwari R; Sampat NY; Chakrabarti I; Parwani AV; Mohanty SK
Am J Clin Pathol; 2024 Jan; 161(1):49-59. PubMed ID: 37639681
[TBL] [Abstract][Full Text] [Related]
11. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity.
Fong D; Spizzo G; Gostner JM; Gastl G; Moser P; Krammel C; Gerhard S; Rasse M; Laimer K
Mod Pathol; 2008 Feb; 21(2):186-91. PubMed ID: 18084248
[TBL] [Abstract][Full Text] [Related]
12. High tumour mutational burden is associated with strong PD-L1 expression, HPV negativity, and worse survival in penile squamous cell carcinoma: an analysis of 165 cases.
Hrudka J; Hojný J; Prouzová Z; Kendall Bártů M; Čapka D; Zavillová N; Matěj R; Waldauf P
Pathology; 2024 Apr; 56(3):357-366. PubMed ID: 38161143
[TBL] [Abstract][Full Text] [Related]
13. Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma.
Tomiyama E; Fujita K; Rodriguez Pena MDC; Taheri D; Banno E; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Takao T; Yamaguchi S; Fushimi H; Yoshimura K; Uemura H; Netto GJ; Nonomura N
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751328
[TBL] [Abstract][Full Text] [Related]
14. Histone methylation defines an epigenetic entity in penile squamous cell carcinoma.
Rogenhofer S; Miersch H; Göke F; Kahl P; Wieland WF; Hofstädter F; Kristiansen G; von Ruecker A; Müller SC; Ellinger J
J Urol; 2013 Mar; 189(3):1117-22. PubMed ID: 22999995
[TBL] [Abstract][Full Text] [Related]
15. [Effect of human trophoblast cell-surface antigen 2 gene expression by RNA interference on proliferation and apoptosis of tongue squamous cell carcinoma and its mechanism].
Fang Z; Chen S; Zhao JF; Sun Q; Qiu F; Li XM
Zhonghua Kou Qiang Yi Xue Za Zhi; 2018 Sep; 53(9):640-644. PubMed ID: 30196628
[No Abstract] [Full Text] [Related]
16. The Prognostic Value of Immune Factors in the Tumor Microenvironment of Penile Squamous Cell Carcinoma.
Ottenhof SR; Djajadiningrat RS; Thygesen HH; Jakobs PJ; Jóźwiak K; Heeren AM; de Jong J; Sanders J; Horenblas S; Jordanova ES
Front Immunol; 2018; 9():1253. PubMed ID: 29942303
[TBL] [Abstract][Full Text] [Related]
17. PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma.
Varki V; Ioffe OB; Bentzen SM; Heath J; Cellini A; Feliciano J; Zandberg DP
Cancer Immunol Immunother; 2018 May; 67(5):805-814. PubMed ID: 29484464
[TBL] [Abstract][Full Text] [Related]
18. Do checkpoint inhibitors provide new hope for management of metastatic penile carcinoma?
Eid R; Nemr E; Haddad FG; Kourie HR; Kattan J
Future Oncol; 2018 Apr; 14(8):677-680. PubMed ID: 29521122
[No Abstract] [Full Text] [Related]
19. Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers.
Nazha B; Zhuang T; Wu S; Brown JT; Magee D; Carthon BC; Kucuk O; Nabhan C; Barata PC; Heath EI; Ryan CJ; McKay RR; Master VA; Bilen MA
Cancer; 2023 Dec; 129(24):3884-3893. PubMed ID: 37565840
[TBL] [Abstract][Full Text] [Related]
20. The value of squamous cell carcinoma antigen in the prognostic evaluation, treatment monitoring and followup of patients with penile cancer.
Zhu Y; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Shen YJ
J Urol; 2008 Nov; 180(5):2019-23. PubMed ID: 18801542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
